img

Global Pemetrexed Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Pemetrexed Drug Industry Research Report, Growth Trends and Competitive Analysis 2024-2034

Pemetrexed (brand name Alimta) is a chemotherapy drug manufactured and marketed by Eli Lilly and Company. Its indications are the treatment of pleural mesothelioma and non-small cell lung cancer.
The global Pemetrexed Drug market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034.
The United States market for Pemetrexed Drug is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The China market for Pemetrexed Drug is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034.
The Europe market for Pemetrexed Drug is estimated to increase from $ million in 2024 to reach $ million by 2034, at a CAGR of % during the forecast period of 2024 through 2034..
The global key manufacturers of Pemetrexed Drug include Eli Lilly and Company, Pfizer, Teva, Eagle Pharmaceuticals, APOTEX, Qilu Pharmaceutical and Biocon, etc. In 2022, the global top five players hold a share approximately % in sales volume, and in term of revenue of Pemetrexed Drug, the top five companies hold a share nearly %.
In terms of sales (consumption) side, this report focuses on the sales of Pemetrexed Drug by regions (Countries), company, by type and by type. from 2018 to 2024 and forecast to 2034.
The global Pemetrexed Drug market is thoroughly, accurately, and comprehensively assessed in the report with a large focus on market dynamics, market competition, regional growth, segmental analysis, and key growth strategies. Buyers of the report will have access to verified market figures, including global market size in terms of revenue and volume. As part of sales analysis, the authors of the report have provided reliable estimations and calculations for global revenue and sales by type segment of the global Pemetrexed Drug market. These figures have been provided in terms of both revenue and sales for the period 2018-2034. Additionally, the report provides accurate figures for sales by region in terms of revenue as well as volume for the same period.



By Company


Eli Lilly and Company
Pfizer
Teva
Eagle Pharmaceuticals
APOTEX
Qilu Pharmaceutical
Biocon
By Type
100 mg lyophilized powder/vial
500 mg lyophilized powder/vial
By Application
Pleural mesothelioma
Non-small cell lung cancer
Sales by Region
North America
U.S.
Canada
China
APAC (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
Europe
Germany
France
U.K.
Italy
Russia
Middle East, Africa, Latin America
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2Sales (consumption), revenue of Pemetrexed Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 3Detailed analysis of Pemetrexed Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 7Europe by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 8China by company, by type and by application, sales, and revenue for each segment.
Chapter 9APAC (excluding China) by company, by type, by application and by region, sales, and revenue for each segment.
Chapter 10Middle East, Africa, and Latin America by company, by type, by application and by country, sales, and revenue for each segment.
Chapter 11Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Pemetrexed Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12Analysis of industrial chain, sales channel, key raw materials, distributors, and customers.
Chapter 13Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14The main points and conclusions of the report.

Table of Content

1 Report Overview
1.1 Pemetrexed Drug Definition
1.2 Market by Type
1.2.1 Global Pemetrexed Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034
1.2.2 100 mg lyophilized powder/vial
1.2.3 500 mg lyophilized powder/vial
1.3 Market Segment by Application
1.3.1 Global Pemetrexed Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034
1.3.2 Pleural mesothelioma
1.3.3 Non-small cell lung cancer
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Pemetrexed Drug Sales
2.1 Global Pemetrexed Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Pemetrexed Drug Revenue by Region: 2018 VS 2022 VS 2034
2.3 Global Pemetrexed Drug Revenue by Region
2.3.1 Global Pemetrexed Drug Revenue by Region (2018-2024)
2.3.2 Global Pemetrexed Drug Revenue by Region (2024-2034)
2.4 Global Pemetrexed Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Pemetrexed Drug Sales Quantity by Region: 2018 VS 2022 VS 2034
2.6 Global Pemetrexed Drug Sales Quantity by Region
2.6.1 Global Pemetrexed Drug Sales Quantity by Region (2018-2024)
2.6.2 Global Pemetrexed Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Pemetrexed Drug Sales Quantity by Manufacturers
3.1.1 Global Pemetrexed Drug Sales Quantity by Manufacturers (2018-2024)
3.1.2 Global Pemetrexed Drug Sales Quantity Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Companies by Pemetrexed Drug Sales in 2022
3.2 Global Pemetrexed Drug Revenue by Manufacturers
3.2.1 Global Pemetrexed Drug Revenue by Manufacturers (2018-2024)
3.2.2 Global Pemetrexed Drug Revenue Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Pemetrexed Drug Revenue in 2022
3.3 Global Pemetrexed Drug Sales Price by Manufacturers
3.4 Global Key Players of Pemetrexed Drug, Industry Ranking, 2021 VS 2022
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Pemetrexed Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Pemetrexed Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Pemetrexed Drug, Product Offered and Application
3.8 Global Key Manufacturers of Pemetrexed Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Pemetrexed Drug Sales Quantity by Type
4.1.1 Global Pemetrexed Drug Historical Sales Quantity by Type (2018-2024)
4.1.2 Global Pemetrexed Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Pemetrexed Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Pemetrexed Drug Revenue by Type
4.2.1 Global Pemetrexed Drug Historical Revenue by Type (2018-2024)
4.2.2 Global Pemetrexed Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Pemetrexed Drug Revenue Market Share by Type (2018-2034)
4.3 Global Pemetrexed Drug Price by Type
4.3.1 Global Pemetrexed Drug Price by Type (2018-2024)
4.3.2 Global Pemetrexed Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Pemetrexed Drug Sales Quantity by Application
5.1.1 Global Pemetrexed Drug Historical Sales Quantity by Application (2018-2024)
5.1.2 Global Pemetrexed Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Pemetrexed Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Pemetrexed Drug Revenue by Application
5.2.1 Global Pemetrexed Drug Historical Revenue by Application (2018-2024)
5.2.2 Global Pemetrexed Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Pemetrexed Drug Revenue Market Share by Application (2018-2034)
5.3 Global Pemetrexed Drug Price by Application
5.3.1 Global Pemetrexed Drug Price by Application (2018-2024)
5.3.2 Global Pemetrexed Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Pemetrexed Drug Sales by Company
6.1.1 North America Pemetrexed Drug Revenue by Company (2018-2024)
6.1.2 North America Pemetrexed Drug Sales Quantity by Company (2018-2024)
6.2 North America Pemetrexed Drug Market Size by Type
6.2.1 North America Pemetrexed Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Pemetrexed Drug Revenue by Type (2018-2034)
6.3 North America Pemetrexed Drug Market Size by Application
6.3.1 North America Pemetrexed Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Pemetrexed Drug Revenue by Application (2018-2034)
6.4 North America Pemetrexed Drug Market Size by Country
6.4.1 North America Pemetrexed Drug Revenue by Country: 2018 VS 2022 VS 2034
6.4.2 North America Pemetrexed Drug Revenue by Country (2018-2034)
6.4.3 North America Pemetrexed Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Pemetrexed Drug Sales by Company
7.1.1 Europe Pemetrexed Drug Sales Quantity by Company (2018-2024)
7.1.2 Europe Pemetrexed Drug Revenue by Company (2018-2024)
7.2 Europe Pemetrexed Drug Market Size by Type
7.2.1 Europe Pemetrexed Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Pemetrexed Drug Revenue by Type (2018-2034)
7.3 Europe Pemetrexed Drug Market Size by Application
7.3.1 Europe Pemetrexed Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Pemetrexed Drug Revenue by Application (2018-2034)
7.4 Europe Pemetrexed Drug Market Size by Country
7.4.1 Europe Pemetrexed Drug Revenue by Country: 2018 VS 2022 VS 2034
7.4.2 Europe Pemetrexed Drug Revenue by Country (2018-2034)
7.4.3 Europe Pemetrexed Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Pemetrexed Drug Sales by Company
8.1.1 China Pemetrexed Drug Sales Quantity by Company (2018-2024)
8.1.2 China Pemetrexed Drug Revenue by Company (2018-2024)
8.2 China Pemetrexed Drug Market Size by Type
8.2.1 China Pemetrexed Drug Sales Quantity by Type (2018-2034)
8.2.2 China Pemetrexed Drug Revenue by Type (2018-2034)
8.3 China Pemetrexed Drug Market Size by Application
8.3.1 China Pemetrexed Drug Sales Quantity by Application (2018-2034)
8.3.2 China Pemetrexed Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Pemetrexed Drug Sales by Company
9.1.1 APAC Pemetrexed Drug Sales Quantity by Company (2018-2024)
9.1.2 APAC Pemetrexed Drug Revenue by Company (2018-2024)
9.2 APAC Pemetrexed Drug Market Size by Type
9.2.1 APAC Pemetrexed Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Pemetrexed Drug Revenue by Type (2018-2034)
9.3 APAC Pemetrexed Drug Market Size by Application
9.3.1 APAC Pemetrexed Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Pemetrexed Drug Revenue by Application (2018-2034)
9.4 APAC Pemetrexed Drug Market Size by Region
9.4.1 APAC Pemetrexed Drug Revenue by Region: 2018 VS 2022 VS 2034
9.4.2 APAC Pemetrexed Drug Revenue by Region (2018-2034)
9.4.3 APAC Pemetrexed Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Pemetrexed Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Company (2018-2024)
10.1.2 Middle East, Africa and Latin America Pemetrexed Drug Revenue by Company (2018-2024)
10.2 Middle East, Africa and Latin America Pemetrexed Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Pemetrexed Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Pemetrexed Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Pemetrexed Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Pemetrexed Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Pemetrexed Drug Revenue by Country: 2018 VS 2022 VS 2034
10.4.2 Middle East, Africa and Latin America Pemetrexed Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Eli Lilly and Company
11.1.1 Eli Lilly and Company Company Information
11.1.2 Eli Lilly and Company Overview
11.1.3 Eli Lilly and Company Pemetrexed Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.1.4 Eli Lilly and Company Pemetrexed Drug Products and Services
11.1.5 Eli Lilly and Company Pemetrexed Drug SWOT Analysis
11.1.6 Eli Lilly and Company Recent Developments
11.2 Pfizer
11.2.1 Pfizer Company Information
11.2.2 Pfizer Overview
11.2.3 Pfizer Pemetrexed Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.2.4 Pfizer Pemetrexed Drug Products and Services
11.2.5 Pfizer Pemetrexed Drug SWOT Analysis
11.2.6 Pfizer Recent Developments
11.3 Teva
11.3.1 Teva Company Information
11.3.2 Teva Overview
11.3.3 Teva Pemetrexed Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.3.4 Teva Pemetrexed Drug Products and Services
11.3.5 Teva Pemetrexed Drug SWOT Analysis
11.3.6 Teva Recent Developments
11.4 Eagle Pharmaceuticals
11.4.1 Eagle Pharmaceuticals Company Information
11.4.2 Eagle Pharmaceuticals Overview
11.4.3 Eagle Pharmaceuticals Pemetrexed Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.4.4 Eagle Pharmaceuticals Pemetrexed Drug Products and Services
11.4.5 Eagle Pharmaceuticals Pemetrexed Drug SWOT Analysis
11.4.6 Eagle Pharmaceuticals Recent Developments
11.5 APOTEX
11.5.1 APOTEX Company Information
11.5.2 APOTEX Overview
11.5.3 APOTEX Pemetrexed Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.5.4 APOTEX Pemetrexed Drug Products and Services
11.5.5 APOTEX Pemetrexed Drug SWOT Analysis
11.5.6 APOTEX Recent Developments
11.6 Qilu Pharmaceutical
11.6.1 Qilu Pharmaceutical Company Information
11.6.2 Qilu Pharmaceutical Overview
11.6.3 Qilu Pharmaceutical Pemetrexed Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.6.4 Qilu Pharmaceutical Pemetrexed Drug Products and Services
11.6.5 Qilu Pharmaceutical Pemetrexed Drug SWOT Analysis
11.6.6 Qilu Pharmaceutical Recent Developments
11.7 Biocon
11.7.1 Biocon Company Information
11.7.2 Biocon Overview
11.7.3 Biocon Pemetrexed Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2024)
11.7.4 Biocon Pemetrexed Drug Products and Services
11.7.5 Biocon Pemetrexed Drug SWOT Analysis
11.7.6 Biocon Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Pemetrexed Drug Value Chain Analysis
12.2 Pemetrexed Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Pemetrexed Drug Production Mode & Process
12.4 Pemetrexed Drug Sales and Marketing
12.4.1 Pemetrexed Drug Sales Channels
12.4.2 Pemetrexed Drug Distributors
12.5 Pemetrexed Drug Customers
13 Market Dynamics
13.1 Pemetrexed Drug Industry Trends
13.2 Pemetrexed Drug Market Drivers
13.3 Pemetrexed Drug Market Challenges
13.4 Pemetrexed Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Pemetrexed Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2022 VS 2034 (US$ Million)
Table 2. Major Manufacturers of 100 mg lyophilized powder/vial
Table 3. Major Manufacturers of 500 mg lyophilized powder/vial
Table 4. Global Pemetrexed Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2022 VS 2034 (US$ Million)
Table 5. Global Pemetrexed Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 6. Global Pemetrexed Drug Revenue by Region (2018-2024) & (US$ Million)
Table 7. Global Pemetrexed Drug Revenue Market Share by Region (2018-2024)
Table 8. Global Pemetrexed Drug Revenue by Region (2024-2034) & (US$ Million)
Table 9. Global Pemetrexed Drug Revenue Market Share by Region (2024-2034)
Table 10. Global Pemetrexed Drug Sales Quantity by Region: 2018 VS 2022 VS 2034 (K Units)
Table 11. Global Pemetrexed Drug Sales by Region (2018-2024) & (K Units)
Table 12. Global Pemetrexed Drug Sales Market Share by Region (2018-2024)
Table 13. Global Pemetrexed Drug Sales by Region (2024-2034) & (K Units)
Table 14. Global Pemetrexed Drug Sales Market Share by Region (2024-2034)
Table 15. Global Pemetrexed Drug Sales Quantity by Manufacturers (2018-2024) & (K Units)
Table 16. Global Pemetrexed Drug Sales Quantity Share by Manufacturers (2018-2024)
Table 17. Global Pemetrexed Drug Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 18. Global Pemetrexed Drug Revenue Share by Manufacturers (2018-2024)
Table 19. Global Pemetrexed Drug Price by Manufacturers 2018-2024 (USD/Unit)
Table 20. Global Key Players of Pemetrexed Drug, Industry Ranking, 2021 VS 2022
Table 21. Global Pemetrexed Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 22. Global Pemetrexed Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Pemetrexed Drug as of 2022)
Table 23. Global Key Manufacturers of Pemetrexed Drug, Manufacturing Base Distribution and Headquarters
Table 24. Global Key Manufacturers of Pemetrexed Drug, Product Offered and Application
Table 25. Global Key Manufacturers of Pemetrexed Drug, Date of Enter into This Industry
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Pemetrexed Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 28. Global Pemetrexed Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 29. Global Pemetrexed Drug Sales Quantity Share by Type (2018-2024)
Table 30. Global Pemetrexed Drug Sales Quantity Share by Type (2024-2034)
Table 31. Global Pemetrexed Drug Revenue by Type (2018-2024) & (US$ Million)
Table 32. Global Pemetrexed Drug Revenue by Type (2024-2034) & (US$ Million)
Table 33. Global Pemetrexed Drug Revenue Share by Type (2018-2024)
Table 34. Global Pemetrexed Drug Revenue Share by Type (2024-2034)
Table 35. Pemetrexed Drug Price by Type (2018-2024) & (USD/Unit)
Table 36. Global Pemetrexed Drug Price Forecast by Type (2024-2034) & (USD/Unit)
Table 37. Global Pemetrexed Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 38. Global Pemetrexed Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 39. Global Pemetrexed Drug Sales Quantity Share by Application (2018-2024)
Table 40. Global Pemetrexed Drug Sales Quantity Share by Application (2024-2034)
Table 41. Global Pemetrexed Drug Revenue by Application (2018-2024) & (US$ Million)
Table 42. Global Pemetrexed Drug Revenue by Application (2024-2034) & (US$ Million)
Table 43. Global Pemetrexed Drug Revenue Share by Application (2018-2024)
Table 44. Global Pemetrexed Drug Revenue Share by Application (2024-2034)
Table 45. Pemetrexed Drug Price by Application (2018-2024) & (USD/Unit)
Table 46. Global Pemetrexed Drug Price Forecast by Application (2024-2034) & (USD/Unit)
Table 47. North America Pemetrexed Drug Revenue by Company (2018-2024) & (US$ Million)
Table 48. North America Pemetrexed Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 49. North America Pemetrexed Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 50. North America Pemetrexed Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 51. North America Pemetrexed Drug Revenue by Type (2018-2024) & (US$ Million)
Table 52. North America Pemetrexed Drug Revenue by Type (2024-2034) & (US$ Million)
Table 53. North America Pemetrexed Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 54. North America Pemetrexed Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 55. North America Pemetrexed Drug Revenue by Application (2018-2024) & (US$ Million)
Table 56. North America Pemetrexed Drug Revenue by Application (2024-2034) & (US$ Million)
Table 57. North America Pemetrexed Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 58. North America Pemetrexed Drug Revenue by Country (2018-2024) & (US$ Million)
Table 59. North America Pemetrexed Drug Revenue by Country (2024-2034) & (US$ Million)
Table 60. North America Pemetrexed Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 61. North America Pemetrexed Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 62. Europe Pemetrexed Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 63. Europe Pemetrexed Drug Revenue by Company (2018-2024) & (US$ Million)
Table 64. Europe Pemetrexed Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 65. Europe Pemetrexed Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 66. Europe Pemetrexed Drug Revenue by Type (2018-2024) & (US$ Million)
Table 67. Europe Pemetrexed Drug Revenue by Type (2024-2034) & (US$ Million)
Table 68. Europe Pemetrexed Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 69. Europe Pemetrexed Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 70. Europe Pemetrexed Drug Revenue by Application (2018-2024) & (US$ Million)
Table 71. Europe Pemetrexed Drug Revenue by Application (2024-2034) & (US$ Million)
Table 72. Europe Pemetrexed Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 73. Europe Pemetrexed Drug Revenue by Country (2018-2024) & (US$ Million)
Table 74. Europe Pemetrexed Drug Revenue by Country (2024-2034) & (US$ Million)
Table 75. Europe Pemetrexed Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 76. Europe Pemetrexed Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 77. China Pemetrexed Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 78. China Pemetrexed Drug Revenue by Company (2018-2024) & (US$ Million)
Table 79. China Pemetrexed Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 80. China Pemetrexed Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 81. China Pemetrexed Drug Revenue by Type (2018-2024) & (US$ Million)
Table 82. China Pemetrexed Drug Revenue by Type (2024-2034) & (US$ Million)
Table 83. China Pemetrexed Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 84. China Pemetrexed Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 85. China Pemetrexed Drug Revenue by Application (2018-2024) & (US$ Million)
Table 86. China Pemetrexed Drug Revenue by Application (2024-2034) & (US$ Million)
Table 87. APAC Pemetrexed Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 88. APAC Pemetrexed Drug Revenue by Company (2018-2024) & (US$ Million)
Table 89. APAC Pemetrexed Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 90. APAC Pemetrexed Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 91. APAC Pemetrexed Drug Revenue by Type (2018-2024) & (US$ Million)
Table 92. APAC Pemetrexed Drug Revenue by Type (2024-2034) & (US$ Million)
Table 93. APAC Pemetrexed Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 94. APAC Pemetrexed Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 95. APAC Pemetrexed Drug Revenue by Application (2018-2024) & (US$ Million)
Table 96. APAC Pemetrexed Drug Revenue by Application (2024-2034) & (US$ Million)
Table 97. APAC Pemetrexed Drug Revenue by Region: 2018 VS 2022 VS 2034 (US$ Million)
Table 98. APAC Pemetrexed Drug Revenue by Region (2018-2024) & (US$ Million)
Table 99. APAC Pemetrexed Drug Revenue by Region (2024-2034) & (US$ Million)
Table 100. APAC Pemetrexed Drug Sales Quantity by Region (2018-2024) & (K Units)
Table 101. APAC Pemetrexed Drug Sales Quantity by Region (2024-2034) & (K Units)
Table 102. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Company (2018-2024) & (K Units)
Table 103. Middle East, Africa and Latin America Pemetrexed Drug Revenue by Company (2018-2024) & (US$ Million)
Table 104. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Type (2018-2024) & (K Units)
Table 105. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 106. Middle East, Africa and Latin America Pemetrexed Drug Revenue by Type (2018-2024) & (US$ Million)
Table 107. Middle East, Africa and Latin America Pemetrexed Drug Revenue by Type (2024-2034) & (US$ Million)
Table 108. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Application (2018-2024) & (K Units)
Table 109. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 110. Middle East, Africa and Latin America Pemetrexed Drug Revenue by Application (2018-2024) & (US$ Million)
Table 111. Middle East, Africa and Latin America Pemetrexed Drug Revenue by Application (2024-2034) & (US$ Million)
Table 112. Middle East, Africa and Latin America Pemetrexed Drug Revenue by Country: 2018 VS 2022 VS 2034 (US$ Million)
Table 113. Middle East, Africa and Latin America Pemetrexed Drug Revenue by Country (2018-2024) & (US$ Million)
Table 114. Middle East, Africa and Latin America Pemetrexed Drug Revenue by Country (2024-2034) & (US$ Million)
Table 115. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Country (2018-2024) & (K Units)
Table 116. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 117. Eli Lilly and Company Company Information
Table 118. Eli Lilly and Company Description and Overview
Table 119. Eli Lilly and Company Pemetrexed Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 120. Eli Lilly and Company Pemetrexed Drug Product and Services
Table 121. Eli Lilly and Company Pemetrexed Drug SWOT Analysis
Table 122. Eli Lilly and Company Recent Developments
Table 123. Pfizer Company Information
Table 124. Pfizer Description and Overview
Table 125. Pfizer Pemetrexed Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 126. Pfizer Pemetrexed Drug Product and Services
Table 127. Pfizer Pemetrexed Drug SWOT Analysis
Table 128. Pfizer Recent Developments
Table 129. Teva Company Information
Table 130. Teva Description and Overview
Table 131. Teva Pemetrexed Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 132. Teva Pemetrexed Drug Product and Services
Table 133. Teva Pemetrexed Drug SWOT Analysis
Table 134. Teva Recent Developments
Table 135. Eagle Pharmaceuticals Company Information
Table 136. Eagle Pharmaceuticals Description and Overview
Table 137. Eagle Pharmaceuticals Pemetrexed Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 138. Eagle Pharmaceuticals Pemetrexed Drug Product and Services
Table 139. Eagle Pharmaceuticals Pemetrexed Drug SWOT Analysis
Table 140. Eagle Pharmaceuticals Recent Developments
Table 141. APOTEX Company Information
Table 142. APOTEX Description and Overview
Table 143. APOTEX Pemetrexed Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 144. APOTEX Pemetrexed Drug Product and Services
Table 145. APOTEX Pemetrexed Drug SWOT Analysis
Table 146. APOTEX Recent Developments
Table 147. Qilu Pharmaceutical Company Information
Table 148. Qilu Pharmaceutical Description and Overview
Table 149. Qilu Pharmaceutical Pemetrexed Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 150. Qilu Pharmaceutical Pemetrexed Drug Product and Services
Table 151. Qilu Pharmaceutical Pemetrexed Drug SWOT Analysis
Table 152. Qilu Pharmaceutical Recent Developments
Table 153. Biocon Company Information
Table 154. Biocon Description and Overview
Table 155. Biocon Pemetrexed Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2024)
Table 156. Biocon Pemetrexed Drug Product and Services
Table 157. Biocon Pemetrexed Drug SWOT Analysis
Table 158. Biocon Recent Developments
Table 159. Key Raw Materials Lists
Table 160. Raw Materials Key Suppliers Lists
Table 161. Pemetrexed Drug Distributors List
Table 162. Pemetrexed Drug Customers List
Table 163. Pemetrexed Drug Market Trends
Table 164. Pemetrexed Drug Market Drivers
Table 165. Pemetrexed Drug Market Challenges
Table 166. Pemetrexed Drug Market Restraints
Table 167. Research Programs/Design for This Report
Table 168. Key Data Information from Secondary Sources
Table 169. Key Data Information from Primary Sources
List of Figures
Figure 1. Pemetrexed Drug Product Picture
Figure 2. Global Pemetrexed Drug Market Size Growth Rate by Type, 2018 VS 2022 VS 2034 (US$ Million)
Figure 3. Global Pemetrexed Drug Market Share by Type in 2022 & 2034
Figure 4. 100 mg lyophilized powder/vial Product Picture
Figure 5. 500 mg lyophilized powder/vial Product Picture
Figure 6. Global Pemetrexed Drug Market Size Growth Rate by Application, 2018 VS 2022 VS 2034 (US$ Million)
Figure 7. Global Pemetrexed Drug Market Share by Application in 2022 & 2034
Figure 8. Pleural mesothelioma
Figure 9. Non-small cell lung cancer
Figure 10. Pemetrexed Drug Report Years Considered
Figure 11. Global Pemetrexed Drug Revenue, (US$ Million), 2018 VS 2022 VS 2034
Figure 12. Global Pemetrexed Drug Revenue 2018-2034 (US$ Million)
Figure 13. Global Pemetrexed Drug Revenue Market Share by Region in Percentage: 2022 Versus 2034
Figure 14. Global Pemetrexed Drug Sales Quantity 2018-2034 (K Units)
Figure 15. Global Pemetrexed Drug Sales Quantity Market Share by Region (2018-2024)
Figure 16. Global Pemetrexed Drug Sales Quantity Market Share by Region (2024-2034)
Figure 17. North America Pemetrexed Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 18. North America Pemetrexed Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 19. Europe Pemetrexed Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 20. Europe Pemetrexed Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 21. China Pemetrexed Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 22. China Pemetrexed Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 23. APAC Pemetrexed Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 24. APAC Pemetrexed Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 26. Middle East, Africa and Latin America Pemetrexed Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. The Top 10 and Top 5 Players Market Share by Pemetrexed Drug Sales Quantity in 2022
Figure 28. The Top 10 and Top 5 Players Market Share by Pemetrexed Drug Revenue in 2022
Figure 29. Pemetrexed Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 30. Global Pemetrexed Drug Sales Quantity Market Share by Type (2018-2034)
Figure 31. Global Pemetrexed Drug Revenue Market Share by Type (2018-2034)
Figure 32. Global Pemetrexed Drug Sales Quantity Market Share by Application (2018-2034)
Figure 33. Global Pemetrexed Drug Revenue Market Share by Application (2018-2034)
Figure 34. North America Pemetrexed Drug Revenue Market Share by Company in 2022
Figure 35. North America Pemetrexed Drug Sales Quantity Market Share by Company in 2022
Figure 36. North America Pemetrexed Drug Sales Quantity Market Share by Type (2018-2034)
Figure 37. North America Pemetrexed Drug Revenue Market Share by Type (2018-2034)
Figure 38. North America Pemetrexed Drug Sales Quantity Market Share by Application (2018-2034)
Figure 39. North America Pemetrexed Drug Revenue Market Share by Application (2018-2034)
Figure 40. North America Pemetrexed Drug Revenue Share by Country (2018-2034)
Figure 41. North America Pemetrexed Drug Sales Quantity Share by Country (2018-2034)
Figure 42. U.S. Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 43. Canada Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 44. Europe Pemetrexed Drug Sales Quantity Market Share by Company in 2022
Figure 45. Europe Pemetrexed Drug Revenue Market Share by Company in 2022
Figure 46. Europe Pemetrexed Drug Sales Quantity Market Share by Type (2018-2034)
Figure 47. Europe Pemetrexed Drug Revenue Market Share by Type (2018-2034)
Figure 48. Europe Pemetrexed Drug Sales Quantity Market Share by Application (2018-2034)
Figure 49. Europe Pemetrexed Drug Revenue Market Share by Application (2018-2034)
Figure 50. Europe Pemetrexed Drug Revenue Share by Country (2018-2034)
Figure 51. Europe Pemetrexed Drug Sales Quantity Share by Country (2018-2034)
Figure 52. Germany Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 53. France Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 54. U.K. Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 55. Italy Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 56. Russia Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 57. China Pemetrexed Drug Sales Quantity Market Share by Company in 2022
Figure 58. China Pemetrexed Drug Revenue Market Share by Company in 2022
Figure 59. China Pemetrexed Drug Sales Quantity Market Share by Type (2018-2034)
Figure 60. China Pemetrexed Drug Revenue Market Share by Type (2018-2034)
Figure 61. China Pemetrexed Drug Sales Quantity Market Share by Application (2018-2034)
Figure 62. China Pemetrexed Drug Revenue Market Share by Application (2018-2034)
Figure 63. APAC Pemetrexed Drug Sales Quantity Market Share by Company in 2022
Figure 64. APAC Pemetrexed Drug Revenue Market Share by Company in 2022
Figure 65. APAC Pemetrexed Drug Sales Quantity Market Share by Type (2018-2034)
Figure 66. APAC Pemetrexed Drug Revenue Market Share by Type (2018-2034)
Figure 67. APAC Pemetrexed Drug Sales Quantity Market Share by Application (2018-2034)
Figure 68. APAC Pemetrexed Drug Revenue Market Share by Application (2018-2034)
Figure 69. APAC Pemetrexed Drug Revenue Share by Region (2018-2034)
Figure 70. APAC Pemetrexed Drug Sales Quantity Share by Region (2018-2034)
Figure 71. Japan Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 72. South Korea Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 73. China Taiwan Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 74. Southeast Asia Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 75. India Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 76. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity Market Share by Company in 2022
Figure 77. Middle East, Africa and Latin America Pemetrexed Drug Revenue Market Share by Company in 2022
Figure 78. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity Market Share by Type (2018-2034)
Figure 79. Middle East, Africa and Latin America Pemetrexed Drug Revenue Market Share by Type (2018-2034)
Figure 80. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity Market Share by Application (2018-2034)
Figure 81. Middle East, Africa and Latin America Pemetrexed Drug Revenue Market Share by Application (2018-2034)
Figure 82. Middle East, Africa and Latin America Pemetrexed Drug Sales Quantity Share by Country (2018-2034)
Figure 83. Middle East, Africa and Latin America Pemetrexed Drug Revenue Share by Country (2018-2034)
Figure 84. Brazil Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 85. Mexico Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 86. Turkey Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 87. Israel Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 88. GCC Countries Pemetrexed Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Pemetrexed Drug Value Chain
Figure 90. Pemetrexed Drug Production Process
Figure 91. Channels of Distribution (Direct Vs Distribution)
Figure 92. Distributors Profiles
Figure 93. Bottom-up and Top-down Approaches for This Report
Figure 94. Data Triangulation
Figure 95. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries